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aBstraCt
The objective of our study was to report the course of the disease in a family affected with autosomal dominant 
neovascular inflammatory vitreoretinopathy (ADNIV, OMIM#193235). ADNIV is a very rare inherited blinding 
disease due to mutations in CAPN5 gene.
We assembled a retrospective observational case series of ADNIV patients. We noticed first symptoms in different 
ages, similar course of the disease and its progression leading in most cases to complete blindness despite treatment.
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introduCtion
Autosomal dominant neovascular inflammatory 
vitreoretinopathy (ADNIV) is an autoimmune uvei-
tis belonging to inherited vitreoretinal dystrophies 
[1]. It is caused by the mutations in CAPN5 gene 
(calpain-5) located on chromosome 11q13 [2, 3]. 
The first scientific work describing ADNIV was 
published in 1990 by Steven Bennett and co-work-
ers [4]. Autosomal dominant neovascular inflam-
matory vitreoretinopathy occurs with a frequency of 
approximately one in 1 000 000 births and has been 
found worldwide [5].
The first symptoms can appear at all ages [5]. 
Autosomal dominant neovascular inflammatory vit-
reoretinopathy is characterized by non-specific uveitis 
in the anterior chamber and vitreous leading to panu-
veitis, iris and retinal neovascularization, cystoid mac-
ular edema, abnormal retinal pigmentation, vitreous 
hemorrhage, intraocular fibrosis with membrane for-
mation and tractional retinal detachment. Sometimes 
we observe the development of secondary glaucoma. 
It is due to uveitic glaucoma, steroid-induced glau-
coma or angle closure glaucoma. The hypotony is also 
observed in ADNIV patients [6].
Unfortunately, despite treatment the disease is 
very progressive and often leads to complete blind-
ness and, subsequently, phthisis. Another character-
istic sign of ADNIV is loss of the b-wave amplitude 
and photoreceptors’ degeneration on electroretinog-
raphy (ERG) recordings [3, 7].
Case report
A retrospective case series was assembled from 
the medical reports of ADNIV patients from 
1988 to present (2019). We reviewed the course 
of illness in 7 of 20 members of a four-generation 
family affected by ADNIV disease — 2 sisters (Pa-
tient 1 — P1, Patient 2 — P2), their father (Patient 
3 — P3), father’s two sisters (Patient 4 — P4, Pa-
tient 5 — P5), Patient’s 5 daughter (Patient 6 — P6) 
and father’s brother (Patient 7 — P7) (Fig. 1). All 
patients provided informed consent for taking part 
in this retrospective study. They were referred to 
our Department due to the suspicious of family 
vitreoretinopathy. Initially the diagnosis was based 
just on a typical clinical history and plotted pedigree 
by geneticist. The patients underwent a complete 
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ophthalmological evaluation. Visual acuity assess-
ment, slit lamp biomicroscopy and fundoscopy 
were performed. The image of macula was observed 
using the optical coherence tomography (OCT) and 
angioOCT. The fundus photographs were recorded. 
The patients were diagnosed using ERG testing (P1, 
P2) and were referred for genetic evaluation (P1, 
P2). The mutations in exon 6 of the CAPN5 gene 
were not found but this does not exclude the pres-
ence of ADNIV, because there are other not exam-
ined fragments of CAPN5 gene.
patient 1
A 20-year-old woman with ADNIV has been 
followed up in our outpatient clinic since 2008. She 
was referred due to previous uveitis and gradual de-
terioration of visual acuity which started when she 
was 9. On examination, her best corrected visual 
acuity (BCVA) was 0.4 in the right eye (OD — ocu-
lus dextra) and 0.6 in the left eye (OS — oculus sinis-
tra). Her anterior segment examination was normal 
in both eyes. We noticed inflammatory cells in the 
vitreous in both eyes. The posterior segment ex-
amination showed normal picture of optic discs and 
narrowing of the arteries. With progression of the 
disease, inflammatory cells in the anterior segment 
and vitreous increased. Her uveitis was managed 
with topical steroids. Because of the central macula 
edema (CME) in both eyes the subtenon triamci-
nolone acetate injections were performed 2 times in 
her OS (2010, 2014) and once in her OD (2010) 
(Fig. 2, 3AB). The cataract started to develop in 
both eyes. She was referred for ERG examination 
where progressive damage to the function of rods 
and cones was determined. On the following exami-
nations we noticed chronic uveitis in the vitreous 
and intraocular fibrosis which obscured the view of 
her fundus.
Genetic examination performed in 2016 raised 
suspicion of autosomal neovascular inflammatory 
vitreoretinopathy. ERG testing in 2017 confirmed 
the diagnosis with reduced b-wave amplitudes and 
photoreceptors degenerations.
On the examination performed recently, her 
BCVA was 0.063 in OD and 0.08 in OS. Mild 
anterior segment uveitis was present. On fundus 
examination, we observed paler optic discs, nar-
rowing of the arteries and veins, chronic CME and 
intraocular fibrosis.
She has been also treated due to hyperthyroidism 
for 3 years.
patient 2
A 15-year-old girl was referred to our outpatient 
clinic for ophthalmological evaluation in 2006. Her 
three years older sister (Patient 1) was treated be-
cause of uveitis of unknown etiology and deteriora-
tion of visual acuity. On the first examination when 
she was 4 years old her visual acuity, the anterior 
and posteriori segments were normal. After 2 years 
of follow up, her BCVA decreased to 0.7 OD and 
0.9 OS. As the disease progressed, inflammatory 
cells in the anterior segment and vitreous were no-
ticed. It resulted in mild media opacity.
She was referred for genetic evaluation in 
2016 where autosomal dominant neovascular in-
flammatory vitreoretinopathy was suspected. ERG 
testing in 2017 confirmed the diagnosis of ADNIV. 
It showed reduced b-wave amplitudes and photore-
ceptors degenerations.
Figure 1. Family tree — affected and nonaffected members of the family
Affected man
Nonaffected man
Affected woman
Nonaffected woman
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Figure 3aB. Patient 1 — cystoid macular edema in optical coherence tomography in the right eye (OD) and diminished central macula 
edema (CME) in the left eye (OS) in 2017
a B
Figure 2. Patient 1 — cystoid macular edema in optical coherence tomography in 2014
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On the last examination, her BCVA was 0.7 in 
both eyes, the anterior segment was normal and 
significant uveitis in the vitreous was noticed. 
On her fundus examination, her optic discs were 
normal, whereas arteries and veins were narrowed 
(Fig. 4AB). The OCT examination revealed signifi-
cant macular thinning in both eyes (Fig. 5AB).
She has been also treated for autoimmunological 
thyroiditis since 2014.
patient 3
A 43-year-old man, a father of Patient 1 and 2. 
His first examination in our outpatient clinic was 
carried out in 2017. His visual acuity started to 
decrease when he was about 7 years old. Now he 
is blind. His OD vision is light perception and OS 
vision — no light perception. He is after cataract 
extraction with IOL implantation in his OD and 
mature cataract in his OS. The iridodonesis is visible 
due to subluxated lenses in both eyes. His pupils 
are distorted because of the posterior synechiae. 
Previously, he was treated due to glaucoma of both 
eyes. Now his eye pressure measurement was nor-
mal: 11 mm Hg in OD and 16 mm Hg in OS. 
The fundus examination was very limited because 
of the significant media opacity especially in OD 
a B
Figure 4aB. Patient 2 — obscured view of the fundus
Figure 5aB. Patient 2 — thinning in the macula in optical coherence tomography in the right eye (OD) and the left eye (OS)
a B
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where the picture of the fundus was grey. In the 
OS, the optic disc was pale; very narrow arteries and 
veins and numerous pigment degenerations were 
visible (Fig. 6). Ultrabiomicroscopy B examination 
revealed vitreous tractions in OD (Fig. 7AB).
He was referred for genetic examination in 
2005 together with his two sisters (Patient 4 and 5). 
The diagnosis of the familial inflammatory neuro-
vitreoretinochoroidopathy was suspected.
He has been also treated for thrombocytopenia 
and splenomegaly.
patient 4
A 45-year-old woman, a sister of Patient 3, was 
examined in our outpatient clinic in 2017. She is 
also blind, like her younger brother (Patient 3). Her 
visual acuity started to deteriorate when she was 
about 6 years old. In 1988, when she was 14 years 
old, she was diagnosed with hereditary neuropathy 
in both eyes. Her visual acuity was 0.1 in both 
eyes. It was treated frequently with intravenous ster-
oids injections and oral steroids. Both eyes cataract 
was noticed in 2002. The familial neurovitreoretino-
choroidopathy was suspected during genetic exami-
nation in 2005 (which she underwent together with 
her brother, Patient 3, and her sister, Patient 5).
Presently her visual acuity is no light perception 
in OD and light perception in OS. On the anterior 
segment examination we noticed iridodonesis due 
to subluxated cataract in both eyes. Grey picture of 
the fundus was caused by significant media opacity. 
Ultrabiomicrocopy B revealed intraocular fibrosis 
in both eyes.
She has been also treated for hypothyroidism 
since 2016. She underwent partially mastectomy 
in 2017.
patient 5
A 32-year-old woman, a sister of Patient 3 and 
4, was referred to our outpatient clinic in 2014 for 
ophthalmological examination. Her vision started 
to deteriorate when she was about 5 years old. In 
2001, optic discs edema and uveitis in both eyes was 
determined. Her BCVA was 0.8 in both eyes. Her 
uveitis and papillitis was treated with intravenous 
and oral steroids. The toxoplasmosis [IgM (–), IgG 
(237)] was also diagnosed and treated in this year.
Figure 6. Patient 3 — thinning in the macula in optical coherence 
tomography
a B
Figure 7aB. Patient 3 — increased density in the vitreous in the right eye (OD) and intraocular fibrosis in the left eye (OS) in ultrabiomi-
croscopy
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She was referred for genetic examination with 
her brother (Patient 3) and her sister (Patient 4) 
and inflammatory neurovitreoretinochoroidopathy 
was suspected. OCT revealed CME in both eyes. It 
was treated with intravitreous triamcinolone acetate 
injections in OS (2009) and in OD (2010). The 
cataracts extractions were performed in both eyes 
in 2012 OD and in 2013 OS. No improvement in 
visual acuity was obtained. With progression of the 
disease, reduction in cystoid macular edema was 
observed (Fig. 8).
On the last examination in 2017, her visual 
acuity in OD was counting fingers from 30 cm and 
OS was just fingers movement before eye. On the 
anterior segment examination, we observed irido-
donesis and on fundus examination — pale optic 
discs and very narrow arteries and veins. Numerous 
inflammatory cells were detected in the vitreous in 
both eyes.
patient 6
A 13-year-old girl, a daughter of Patient 4, was 
examined in 2010 because of blurred vision in one 
eye. Her BCVA in OD was 1.0 and in OS was 
0.6. The anterior segment examination was normal 
but posterior segment revealed CME in OCT exam. 
It was treated with topical non-steroidal anti-in-
flammatory eye drops and oral acetazolamide.
It was her first and last ophthalmological ex-
amination. Unfortunately, she died in car accident 
when she was 14 years old.
patient 7
A 37-year-old man, a brother of Patient 3, Pa-
tient 4 and 5 Patient 5, was referred to our outpa-
tient clinic in 2009 due to a decrease in his visual 
acuity in both eyes. His vision started to deteriorate 
at the end of the third decade of life. On the first 
visit the vitreoretinitis and CME in both eyes were 
diagnosed. He was treated with intravenous and oral 
steroids. His visual acuity was 0.3 in OD and 0.2 in 
OS. There was no improvement despite applied 
treatment. Next triamcinolone acetate injections in 
OS (2009) and in OD (2012) and subtenon steroid 
injection in OS (2010) were made. In 2012, the 
vitrectomy with ILM peeling in his OS was per-
formed. Despite the treatment, the cystoid macular 
edema was present in OS and normal macula in 
OD was observed in 2015. Two years later swelling 
in the macula was detected in both eyes (Fig. 9AB, 
10AB). The measurement of his intraocular pres-
sure in OD was higher (28 mm Hg) in 2012. It was 
managed with topical antiglaucoma drops.
On the last examination his BCVA was 0.1 in 
both eyes. Anterior segment examination was nor-
mal. There was mild inflammation in the vitreous 
Figure 8. Patient 5 — diminishing of cystoid macular edema in optical coherence tomography in OU
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in both eyes. In OCT exam we noticed significant 
thinning in the macula in both eyes. Additionally he 
smokes cigarettes and abuses alcohol.
disCussion
Autosomal dominant neovascular inflamma-
tory vitreoretinopathy (ADNIV) is a very serious 
disease leading to loss of vision. It is classified as 
a rare disease. The diagnosis of the illness is very 
difficult because its symptoms mimic much more 
common eye conditions like uveitis, retinitis pig-
mentosa, rod-cone dystrophy, proliferative vitre-
oretinopathy and diabetic retinopathy [4, 7–9]. 
A very characteristic sign of ADNIV is lack of 
systemic features [1]. 
a B
Figure 9aB. Patient 7 — normal macula in the right eye (OD) and cystoid macular edema in the left eye (OS) in optical coherence  
tomography in 2015
Figure 10aB. Patient 7 — swelling in the macula in the right eye (OD) and in the left eye (OS) in optical coherence tomography in 2017
a B
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The symptoms of the disease are divided into 
5 stages, each lasting approximately ten years [10] 
The affected members of the family showed clini-
cal signs of ADNIV disease previously reported by 
other authors [2, 11, 12], including non-infectious 
uveitis in the anterior segment and vitreous, cystoid 
macular edema, epiretinal membrane formation, 
proliferative vitreoretinopathy, cataract, neovascu-
lar glaucoma and, ultimately, blindness. Like other 
authors, we observed asymmetric disease progres-
sion between the eyes of affected patient and also 
between affected members of the family. The clinical 
severity of the disease was indistinguishable among 
affected males and females. 
The first symptoms can start at all ages [5]. 
In our series, first symptoms occurred in the first 
decade of life in all patients except Patient 7. His 
visual acuity started to decrease at the end of the 
third decade of life. We observed significant dete-
rioration of visual acuity with age in all patients 
(Tab. 1). Over the years, with disease progression 
there were different but characteristic symptoms 
of ADNIV in each patient. We noticed recurrent 
uveitis in the anterior segment in the majority of 
patients and inflammation in the vitreous in all 
patients. The cataract formation was also observed 
in all patients, even in the youngest ones (Patient 
1 and 2). The papilledema was noticed in three 
patients: Patient 3, 4 and 5. OCT detected CME 
in Patient 1, 6, and 7; preretinal membrane in 
Patient 2 and thinning in the macula in Patient 
2 and 7. We also observed raised intraocular pres-
sure in Patient 3, 4 and 7. The examination of the 
anterior segment revealed the presence of irido-
donesis in patients with cataract (Patient 4) and 
after extraction of cataract (Patient 3 and 5). All 
patients had more or less significant media opacity 
due to ongoing inflammation in the vitreous and 
intraocular fibrosis which especially obscured view 
of the fundus. Disease progression was observed in 
all patients. They showed the signs of stage II/III 
(Patient 1, 2, 6 and 7) and stage IV (Patient 3, 
4 and 5) ADNIV. 
On electroretinography loss of the b-wave 
was recorded.
In our genetic analysis (Patient 1and 2), the 
mutations in exon 6 of the CAPN5 gene were not 
detected but this does not exclude the presence of 
ADNIV disease because other fragments of the gene 
was not examined. Exon 6 of the CAPN5 gene was 
subjected to genetic testing because other authors 
[3] reported mutations in this exon.
Treatment of ADNIV poses many challeng-
es. The pathophysiology and immunopathology are 
still unknown and for this reason the treatment 
is symptomatic rather than specific. The manage-
ment of chronic immune-mediated uveitis is often 
very difficult and ineffective [13]. The patients re-
ceived repeated injections of immunosuppressive 
medications to control cystoid macular edema and 
intraocular inflammation, but in all of them the dis-
ease progressed despite treatment. Long-term local 
and systemic steroid therapies are limited because 
of the numerous side effects. Some authors report 
the benefit of the fluocinolone acetonide (FA) im-
plant in the treatment of chronic uveitis in ADNIV 
patients [13].
In our series we observed deterioration of visual 
acuity despite recommended continuous treatment.
ConClusion
Autosomal dominant neovascular inflammatory 
vitreoretinopathy is a very serious progressive dis-
ease. Medical therapy for ADNIV has limited effi-
cacy. Despite the aggressive treatment, we observed 
deterioration of visual acuity due to severe compli-
cations of the disease. The patients with ADNIV 
require constant ophthalmological care. Further 
investigations including immunology, physiology 
and genetics are necessary to better understand AD-
NIV pathogenesis.
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